ORASURE TECHNOLOGIES INC — fact timeline

ORASURE TECHNOLOGIES INC: Amendment to declassify the board of directors over a three-year period beginning at the fiscal 2027 annual meeting, so that all directors will be elected annually (effective 2026-06-03).

“As further described in Item 5.07 to this Current Report on Form 8-K, at the Annual Meeting, the stockholders of the Company approved an amendment (the “Amendment”) to the Company’s Certificate of Incorporation to declassify the Company’s board of directors (the “Board of Directors”) over a three-year period, beginning at the fiscal 2027 annual meeting of stockholders, such that from and after the fiscal 2027 annual meeting, all directors who are up for election at an annual meeting of stockholders will be elected to serve for a term of one year and until such directors’ successors are duly elected and qualified or until such directors’ earlier death, resignation or removal. On June 3, 2026, the Company filed a Certificate of Amendment to the Company’s Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware and the Certificate of Amendment became effective on filing.”

ORASURE TECHNOLOGIES INC shareholders approved Amendment to the Company’s Certificate of Incorporation to Declassify the Board of Directors and Add Certain Clarifying Changes at the 2026-06-03 meeting.

“ITEM 5 . Amendment to the Company’s Certificate of Incorporation to Declassify the Board of Directors and Add Certain Clarifying Changes Votes For Votes Against Abstentions Broker Non-Votes 49,125,748 2,223,960 117,452 10,579,208”

ORASURE TECHNOLOGIES INC shareholders approved Approval of an Amendment and Restatement of the Stock Award Plan to Increase the Shares Authorized For Issuance Thereunder at the 2026-06-03 meeting.

“ITEM 4 . Approval of an Amendment and Restatement of the Stock Award Plan to Increase the Shares Authorized For Issuance Thereunder. Votes For Votes Against Abstentions Broker Non-Votes 57,055,163 4,796,974 194,231 0”

ORASURE TECHNOLOGIES INC shareholders approved Advisory (Non-Binding) Vote to Approve the Resolution on the Company’s Executive Compensation at the 2026-06-03 meeting.

“ITEM 3. Advisory (Non-Binding) Vote to Approve the Resolution on the Company’s Executive Compensation. Votes For Votes Against Abstentions Broker Non-Votes 45,225,131 6,179,090 62,939 10,579,208”

ORASURE TECHNOLOGIES INC shareholders approved Ratification of the Appointment of Grant Thornton LLP as the Company’s Independent Registered Public Accounting Firm for Fiscal Year 2026 at the 2026-06-03 meeting.

“ITEM 2 . Ratification of the Appointment of Grant Thornton LLP as the Company’s Independent Registered Public Accounting Firm for Fiscal Year 2026. Votes For Votes Against Abstentions 59,891,739 2,143,244 11,385”

ORASURE TECHNOLOGIES INC shareholders approved Election of Three Class II Directors for Terms Ending in 2029 at the 2026-06-03 meeting.

“ITEM 1 . Election of Three (3) Class II Directors for Terms Ending in 2029. NAME Votes For Votes Against Abstentions Broker Non-Votes John D. Bertrand 47,822,139 3,366,544 278,477 10,579,208 Steven K. Boyd 48,806,872 2,596,468 63,820 10,579,208 Robert W. McMahon 47,770,768 3,583,027 113,365 10,579,208”

ORASURE TECHNOLOGIES INC reported financial results for the quarter ended March 31, 2026.

“On May 6, 2026, OraSure Technologies, Inc. (the “Company”) issued a press release announcing its consolidated financial results for the quarter ended March 31, 2026”

ORASURE TECHNOLOGIES INC entered into Cooperation Agreement with Altai Capital Management, L.P. and Altai Capital Management, LLC (collectively, Altai) (effective 2026-04-16).

“On April 16, 2026, OraSure Technologies, Inc. (the “Company”) announced its entry into a cooperation agreement (the “Cooperation Agreement”) with Altai Capital Management, L.P. and Altai Capital Management, LLC (collectively, “Altai”).”

Kathleen G. Weber resigned as Chief Product Officer at ORASURE TECHNOLOGIES INC.

“On May 8, 2025, Kathleen G. Weber notified OraSure Technologies, Inc. (the “Company”) of her resignation as Chief Product Officer of the Company, effective June 30, 2025.”

ORASURE TECHNOLOGIES INC completed an acquisition involving Sherlock Biosciences, Inc. for $5 million (closed 2024-12-19).

“by the Company in connection with the Merger pursuant to the Merger Agreement consists of, subject to the terms and conditions of the Merger Agreement: (i) an upfront payment of $5 million (such payment, the “Initial Merger Consideration”), plus certain legal expenses and directors’ and officers’ tail policy insurance costs, (ii) two milestone payments of up to an”

John P. Kenny was appointed as Director at ORASURE TECHNOLOGIES INC.

“the Board appointed John P. Kenny as a new member of the Board, with such appointment to be effective as of the Effective Date.”

ORASURE TECHNOLOGIES INC: Amendment to Certificate of Incorporation to limit officer liability, as permitted by recent Delaware law amendments (effective 2024-05-16).

“As further described in Item 5.07 to this Current Report on Form 8-K, at the Annual Meeting, the stockholders of the Company approved an amendment (the “Amendment”) to the Company’s Certificate of Incorporation to limit the liability of certain officers of the Company as permitted by recent amendments to Delaware law. On May 16, 2024, the Company filed a Certificate of Amendment to the Company’s Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware and the Certificate of Amendment became effective on filing.”

ORASURE TECHNOLOGIES INC shareholders approved Approval to Adjourn the Annual Meeting to a Later Date or Dates at the 2024-05-14 meeting.

“ITEM 6 . Approval to Adjourn the Annual Meeting to a Later Date or Dates, If Necessary or Appropriate, to Permit Further Solicitation and Vote of Proxies in the Event That There are Insufficient Votes for, or Otherwise, in Connection with the Approval of the Foregoing Proposals. Votes For Votes Against Abstentions 50,515,683 16,580,420 33,979”

ORASURE TECHNOLOGIES INC shareholders approved Approval of an Amendment and Restatement of the Stock Award Plan to Increase the Shares Authorized for Issuance Thereunder at the 2024-05-14 meeting.

“ITEM 5 . Approval of an Amendment and Restatement of the Stock Award Plan to Increase the Shares Authorized for Issuance Thereunder. Votes For Votes Against Abstentions Broker Non-Votes 56,999,751 5,034,883 88,291 5,007,157”

ORASURE TECHNOLOGIES INC shareholders approved Approval of an amendment to the Company's Certificate of Incorporation at the 2024-05-14 meeting.

“ITEM 4 . Approval of an amendment to the Company's Certificate of Incorporation. Votes For Votes Against Abstentions Broker Non-Votes 54,132,675 7,945,995 44,255 5,007,157”

ORASURE TECHNOLOGIES INC shareholders approved Advisory (Non-Binding) Vote to Approve the Resolution on the Company's Executive Compensation at the 2024-05-14 meeting.

“ITEM 3. Advisory (Non-Binding) Vote to Approve the Resolution on the Company's Executive Compensation. Votes For Votes Against Abstentions Broker Non-Votes 57,538,779 4,472,675 111,471 5,007,157”

ORASURE TECHNOLOGIES INC shareholders approved Ratification of the Appointment of Grant Thornton LLP as the Company's Independent Registered Public Accounting Firm for Fiscal Year 2024 at the 2024-05-14 meeting.

“ITEM 2 . Ratification of the Appointment of Grant Thornton LLP as the Company's Independent Registered Public Accounting Firm for Fiscal Year 2024. Votes For Votes Against Abstentions 64,912,239 2,158,172 59,671”

ORASURE TECHNOLOGIES INC shareholders approved Election of two Class III Directors for Terms Ending in 2027 at the 2024-05-14 meeting.

“ITEM 1 . Election of two Class III Directors for Terms Ending in 2027. NAME Votes For Votes Against Abstentions Broker Non-Votes Nancy J. Gagliano, M.D. 57,243,711 4,832,639 46,575 5,007,157 Lelio Marmora 57,332,773 4,732,865 57,287 5,007,157”

ORASURE TECHNOLOGIES INC reported financial results for quarter ended March 31, 2024.

“On May 8, 2024, OraSure Technologies, Inc. (the “Company”) issued a press release announcing its consolidated financial results for the quarter ended March 31, 2024 and certain other matters.”

ORASURE TECHNOLOGIES INC disclosed a cybersecurity incident: An unauthorized third party gained access to Company data from certain information systems, and certain files were exfiltrated. Impact: The incident has not had a material impact on operations, financial systems, or financial condition, and the Company does not anticipate a material impact moving forward. Information systems are operational. Company determined it not material. Discovered 2024-03-27.

“On or about March 27, 2024, OraSure Technologies, Inc. (the “Company”) became aware of a cybersecurity incident in which an unauthorized third party gained access to Company data from certain information systems.”

ORASURE TECHNOLOGIES INC reported financial results for the full year and quarter ended December 31, 2023.

“OraSure Technologies, Inc. (the “Company”) issued a press release announcing its consolidated financial results for the full year and quarter ended December 31, 2023 and certain other matters.”

ORASURE TECHNOLOGIES INC engaged Grant Thornton LLP as its auditor.

“The Committee and the Board approved the appointment of Grant Thornton LLP (" GT ") as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024, which will become effective immediately upon the dismissal of KPMG.”

ORASURE TECHNOLOGIES INC dismissed KPMG LLP as its auditor.

“As a result of this process, on November 29, 2023, the Company notified KPMG that it will dismiss KPMG, which is currently serving as the Company's independent auditors, upon completion of their audit of the Company's consolidated financial statements as of and for the year ended December 31, 2023 and the effectiveness of the Company's internal control over financial reporting as of December 31, 2023, and the issuance of their reports thereon.”

ORASURE TECHNOLOGIES INC reported financial results for quarter ended September 30, 2023.

“On November 7, 2023, OraSure Technologies, Inc. (the “Company”) issued a press release announcing its consolidated financial results for the quarter ended September 30, 2023”

ORASURE TECHNOLOGIES INC reported financial results for the quarter ended June 30, 2023.

“On August 3, 2023, OraSure Technologies, Inc. (the “Company”) issued a press release announcing its consolidated financial results for the quarter ended June 30, 2023 and certain other matters.”

Robert W. McMahon was appointed as Class II Director at ORASURE TECHNOLOGIES INC.

“the Board appointed Robert W. McMahon as a new member of the Board, with such appointment to be effective as of the Effective Date.”

ORASURE TECHNOLOGIES INC shareholders rejected Approval of Stockholder Proposal Regarding Greenhouse Gas Reduction Targets at the 2023-05-16 meeting.

“Item 6 – Approval of Stockholder Proposal Regarding Greenhouse Gas Reduction Targets Votes For Votes Against Abstentions Broker Non-Votes 4,444,629 54,636,082 411,038 6,378,873”

ORASURE TECHNOLOGIES INC shareholders approved Approval of the Company's Amended and Restated Stock Award Plan to Increase the Shares Authorized for Issuance Thereunder at the 2023-05-16 meeting.

“Item 5 – Approval of the Company’s Amended and Restated Stock Award Plan to Increase the Shares Authorized for Issuance Thereunder. Votes For Votes Against Abstentions Broker Non-Votes 51,316,459 8,094,790 80,500 6,378,873”

ORASURE TECHNOLOGIES INC shareholders approved Advisory (Non-Binding) Vote to Select the Frequency of Future Stockholder Advisory Votes to Approve the Company's Executive Compensation at the 2023-05-16 meeting.

“Item 4 – Advisory (Non-Binding) Vote to Select the Frequency of Future Stockholder Advisory Votes to Approve the Company’s Executive Compensation. 3 Years 2 Years Every Year Abstentions Broker Non-Votes 3,632,289 65,308 55,752,085 42,067 6,378,873”

ORASURE TECHNOLOGIES INC shareholders approved Advisory (Non-Binding) vote to Approve the Resolution on the Company's Executive Compensation at the 2023-05-16 meeting.

“Item 3 - Advisory (Non-Binding) vote to Approve the Resolution on the Company’s Executive Compensation. Votes For Votes Against Abstentions Broker Non-Votes 39,391,642 20,030,810 69,297 6,378,873”

ORASURE TECHNOLOGIES INC shareholders approved Ratification of the Appointment of KPMG LLP as the Company's Independent Registered Public Accounting Firm for Fiscal Year 2023 at the 2023-05-16 meeting.

“Item 2 – Ratification of the Appointment of KPMG LLP as the Company’s Independent Registered Public Accounting Firm for Fiscal Year 2023. Votes For Votes Against Abstentions 64,607,502 1,204,485 58,635”

ORASURE TECHNOLOGIES INC shareholders approved Election of One Class II Director for a Term Ending in 2026 at the 2023-05-16 meeting.

“Item 1 - Election of One Class II Director for a Term Ending in 2026. Nominee Votes For Votes Against Abstentions Broker Non-Votes Mara G. Aspinall 54,364,938 5,099,608 27,203 6,378,873”

ORASURE TECHNOLOGIES INC: Amended and restated bylaws to address universal proxy rules (effective 2023-05-09).

“the board of directors of the Company approved and adopted the Second Amended and Restated Bylaws, effective May 9, 2023”

ORASURE TECHNOLOGIES INC reported three months ended March 31, 2023 results: revenue $ 154,963, net income 27,219, EPS $ 0.37.

“Three Months Ended March 31, 2023 2022 % Change Core Business $ 36,554 $ 36,675 0 % COVID-19 118,409 31,032 282 Total Net Revenue $ 154,963 $ 67,707 129 % Three Months Ended March 31, 2023 2022 % Change Net revenues $ 154,963 $ 67,707 129 % Gross profit 65,815 24,299 171 Gross margin 42.5 % 35.9 % Non-GAAP gross profit 66,277 25,527 160 Non-GAAP gross margin 42.8 % 37.7 % Operating income (loss) 24,321 (16,172 ) NM Operating margin 15.7 % -23.9 % Non-GAAP operating income (loss) 32,658 (6,584 ) NM Non-GAAP operating income (loss) 21.1 % -9.7 % Net income (loss) 27,219 (19,940 ) NM Non-GAAP net income (loss) 34,454 (10,662 ) NM GAAP EPS $ 0.37 $ (0.28 ) NM Non-GAAP EPS $ 0.47 $ (0.15 ) NM”

Scott Gleason resigned as Senior Vice President of Corporate Communications and Investor Relations at ORASURE TECHNOLOGIES INC.

“On March 15, 2023, Scott Gleason, who currently serves as the Company’s Senior Vice President of Corporate Communications and Investor Relations, notified the Company of his resignation from the Company, effective May 26, 2023, in order to pursue another opportunity.”

ORASURE TECHNOLOGIES INC reported Q4 2022 results: revenue $123,078, net income 15,561, EPS $0.21.

“Financial Highlights Three Months Ended Year Ended December 31, December 31, 2022 2021 % Change 2022 2021 % Change Core Diagnostics $ 18,400 $ 17,898 3 % $ 70,007 $ 67,333 4 % InteliSwab 88,857 14,770 502 233,666 22,707 929 Total Diagnostics 107,257 32,668 228 303,673 90,040 237 Core Molecular Solutions 15,684 22,936 (32 ) 74,147 89,467 (17 ) COVID-19 kits 137 7,964 (98 ) 9,659 54,167 (82 ) Total Molecular Solutions 15,821 30,900 (49 ) 83,806 143,634 (42 ) Total Revenue $ 123,078 $ 63,568 94 % $ 387,479 $ 233,674 66 % Three Months Ended Year ended December 31, December 31, 2022 2021 % Change 2022 2021 % Change Net revenues $ 123,078 $ 63,568 94 % $ 387,479 $ 233,674 66 % Gross profit 49,589 27,133 83 147,637 117,600 26 Gross margin 40 % 43 % 38 % 50 % Non-GAAP gross profit 50,126 28,685 75 154,464 121,708 27 Non-GAAP gross margin 41 % 45 % 40 % 52 % Operating income (loss) 13,435 (9,371 ) NM (22,957 ) (10,164 ) NM Operating margin 11 % -15 % -6 % -4 % Non-GAAP operating income (loss) 1”

Kathleen G. Weber was appointed as Chief Product Officer at ORASURE TECHNOLOGIES INC.

“On November 7, 2022, the board of directors of OraSure Technologies, Inc. (the “Company”) appointed Kathleen G. Weber, the Company’s current President of Molecular Solutions, as the Company’s Chief Product Officer, effective November 14, 2022.”

ORASURE TECHNOLOGIES INC reported the three months ended September 30, 2022 results: revenue $116.5 million, net income $5,273, EPS 0.07.

“Communications 484-425-0588 sgleason@orasure.com Media Contact: Amy Koch Sr. Mgr. Corporate Communications 484-523-1815 media@orasure.com OraSure Reports 3Q22 Record Revenue of $116.5 Million Growing 116% Year-Over-Year InteliSwab® revenue of $79.6 million in Q3, up 85% sequentially; Company continues to expand test production capacity Company wins new contracts for”

Scott Gleason departed as Interim Chief Financial Officer at ORASURE TECHNOLOGIES INC.

“Mr. McGrath will succeed Mr. Scott Gleason, who has served as the Company’s Interim Chief Financial Officer since September 2021.”

Ken McGrath was appointed as Chief Financial Officer at ORASURE TECHNOLOGIES INC.

“On August 8, 2022, the board of directors (the “Board”) of OraSure Technologies, Inc. (the “Company”) appointed Ken McGrath as the Company’s Chief Financial Officer, effective August 8, 2022 (the “Effective Date”).”

Kathleen G. Weber departed as President of Molecular Solutions at ORASURE TECHNOLOGIES INC.

“Ms. Weber has notified the Company of her decision to rescind her resignation as President of Molecular Solutions.”

Agnieszka M. Gallagher departed as Executive Vice President, General Counsel and Chief Compliance Officer at ORASURE TECHNOLOGIES INC.

“On June 3, 2022, Agnieszka M. Gallagher, who currently serves as OraSure Technologies, Inc.’s (the “Company”) Executive Vice President, General Counsel and Chief Compliance Officer, notified the Company of her termination of her employment with the Company with Good Reason (as defined in her employment agreement, dated as of November 29, 2021) related to Company organizational changes.”

Nancy J. Gagliano departed as Interim Chief Executive Officer at ORASURE TECHNOLOGIES INC.

“Dr. Gagliano will resign, effective June 4, 2022, from her position as the Company’s interim Chief Executive Officer.”

Carrie Eglinton Manner was appointed as Class I Director at ORASURE TECHNOLOGIES INC.

“Ms. Eglinton Manner will be appointed by the Board to serve as a Class I director on the Board as of the Effective Date.”

Carrie Eglinton Manner was appointed as President and Chief Executive Officer at ORASURE TECHNOLOGIES INC.

“the board of directors (the “Board”) of the Company will appoint Ms. Eglinton Manner as the Company’s President and Chief Executive Officer, effective June 4, 2022”

Nancy J. Gagliano was appointed as Interim Chief Executive Officer at ORASURE TECHNOLOGIES INC.

“appointed Nancy J. Gagliano, M.D., M.B.A., a current director of the Company, to serve as the Company’s Interim Chief Executive Officer”

Stephen S. Tang was terminated as President and Chief Executive Officer at ORASURE TECHNOLOGIES INC.

“following the termination of Stephen S. Tang as a director and the Company’s President and Chief Executive Officer on March 31, 2022”

Lisa Nibauer changed role as President of Diagnostics at ORASURE TECHNOLOGIES INC.

“Effective as of December 31, 2021, Lisa Nibauer, the Company’s current Executive Vice President, Business Unit Leader, Diagnostics, will become President of Diagnostics.”

Stephen S. Tang departed as President and Chief Executive Officer at ORASURE TECHNOLOGIES INC.

“Stephen S. Tang, the Company’s President and Chief Executive Officer, will be leaving the Company as of March 31, 2022.”

Agnieszka M. Gallagher was appointed as General Counsel, Chief Compliance Officer and Secretary at ORASURE TECHNOLOGIES INC.

“Ms. Agnieszka M. Gallagher who will join the Company on November 29, 2021 after most recently serving as Chief Ethics and Compliance Officer at Alhylam Pharmaceuticals.”